MedTrace Logo

Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease

NCT01605513 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2016-01-26

No results posted yet for this study

Summary

The purpose of this study is to determine whether PEG-IFN-SA is safe, tolerant and effective in the treatment of HCV patients.

Conditions

  • Hepatitis C Virus

Interventions

DRUG

interferon

PEG-IFN-SA (new interferon) was injected subcutaneously one times per week for 12 times.

Sponsors & Collaborators

  • The First Hospital of Jilin University

    lead OTHER

Principal Investigators

  • yanhua ding, associate professor · First Hospital, Jilin University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01605513 on ClinicalTrials.gov